Cargando…
Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP
In patients with intermediate or high grade non-Hodgkin lymphoma (NHL), third generation chemotherapy regimens have been introduced to improve survival in comparison with the standard CHOP regimen. However, most studies have found no difference between these two treatments. We conducted a meta-analy...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363752/ https://www.ncbi.nlm.nih.gov/pubmed/11161392 http://dx.doi.org/10.1054/bjoc.2000.1566 |
_version_ | 1782153782620061696 |
---|---|
author | Messori, A Vaiani, M Trippoli, S Rigacci, L Jerkeman, M Longo, G |
author_facet | Messori, A Vaiani, M Trippoli, S Rigacci, L Jerkeman, M Longo, G |
author_sort | Messori, A |
collection | PubMed |
description | In patients with intermediate or high grade non-Hodgkin lymphoma (NHL), third generation chemotherapy regimens have been introduced to improve survival in comparison with the standard CHOP regimen. However, most studies have found no difference between these two treatments. We conducted a meta-analysis to assess the effectiveness of third generation regimens as compared with CHOP. Our study included the randomized controlled trials published in English from 1970 to 1999. After a Medline search, 5 trials were found to meet our inclusion criteria. A total of 1982 patients, that were enrolled in these trials, were included in the survival meta-analysis. Our methodology retrieved patient-level information from all of these subjects; survival up to 9 years after randomization was compared between the two treatment options. The results of our meta-analysis showed that, in comparison with CHOP, third generation chemotherapy did not prolong survival at levels of statistical significance (chi-square by log-rank test = 1.44, P = 0.23). The relative death risk for third generation regimens vs. CHOP was 0.92 (95%CI: 0.80 to 1.06;P = 0.26). We conclude that, on the basis of our meta-analysis, third generation regimens do not confer any survival benefit to patients with intermediate or high grade NHL as compared with CHOP. © 2001 Cancer Research Campaign http://www.bjcancer.com |
format | Text |
id | pubmed-2363752 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2001 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23637522009-09-10 Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP Messori, A Vaiani, M Trippoli, S Rigacci, L Jerkeman, M Longo, G Br J Cancer Regular Article In patients with intermediate or high grade non-Hodgkin lymphoma (NHL), third generation chemotherapy regimens have been introduced to improve survival in comparison with the standard CHOP regimen. However, most studies have found no difference between these two treatments. We conducted a meta-analysis to assess the effectiveness of third generation regimens as compared with CHOP. Our study included the randomized controlled trials published in English from 1970 to 1999. After a Medline search, 5 trials were found to meet our inclusion criteria. A total of 1982 patients, that were enrolled in these trials, were included in the survival meta-analysis. Our methodology retrieved patient-level information from all of these subjects; survival up to 9 years after randomization was compared between the two treatment options. The results of our meta-analysis showed that, in comparison with CHOP, third generation chemotherapy did not prolong survival at levels of statistical significance (chi-square by log-rank test = 1.44, P = 0.23). The relative death risk for third generation regimens vs. CHOP was 0.92 (95%CI: 0.80 to 1.06;P = 0.26). We conclude that, on the basis of our meta-analysis, third generation regimens do not confer any survival benefit to patients with intermediate or high grade NHL as compared with CHOP. © 2001 Cancer Research Campaign http://www.bjcancer.com Nature Publishing Group 2001-02 /pmc/articles/PMC2363752/ /pubmed/11161392 http://dx.doi.org/10.1054/bjoc.2000.1566 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Messori, A Vaiani, M Trippoli, S Rigacci, L Jerkeman, M Longo, G Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP |
title | Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP |
title_full | Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP |
title_fullStr | Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP |
title_full_unstemmed | Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP |
title_short | Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP |
title_sort | survival in patients with intermediate or high grade non-hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with chop |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363752/ https://www.ncbi.nlm.nih.gov/pubmed/11161392 http://dx.doi.org/10.1054/bjoc.2000.1566 |
work_keys_str_mv | AT messoria survivalinpatientswithintermediateorhighgradenonhodgkinslymphomametaanalysisofrandomizedstudiescomparingthirdgenerationregimenswithchop AT vaianim survivalinpatientswithintermediateorhighgradenonhodgkinslymphomametaanalysisofrandomizedstudiescomparingthirdgenerationregimenswithchop AT trippolis survivalinpatientswithintermediateorhighgradenonhodgkinslymphomametaanalysisofrandomizedstudiescomparingthirdgenerationregimenswithchop AT rigaccil survivalinpatientswithintermediateorhighgradenonhodgkinslymphomametaanalysisofrandomizedstudiescomparingthirdgenerationregimenswithchop AT jerkemanm survivalinpatientswithintermediateorhighgradenonhodgkinslymphomametaanalysisofrandomizedstudiescomparingthirdgenerationregimenswithchop AT longog survivalinpatientswithintermediateorhighgradenonhodgkinslymphomametaanalysisofrandomizedstudiescomparingthirdgenerationregimenswithchop |